Ram Bishnoi, MD
Psychiatry · Tampa, FLNPI 1780963835
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 67 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Alkermes, Inc. at 53.1% of the total. Reporting peaked in 2021 at $431 and has fallen 91.9% since, to $35 in 2025.
Across 67 payments — averaging $24.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$869
- Sunovion Pharmaceuticals Inc.$162
- Otsuka America Pharmaceutical, Inc.$156
- Lundbeck LLC$136
- Johnson & Johnson$133
- Greenwich Biosciences, Inc.$52
- plus $128 from 7 others
Across 9 payments — averaging $5610.94 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$29K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$22K
What the payments were for
- Food & beverage$1,636100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$492
- LATUDA$122
- ABILIFY MAINTENA$114
How this compares
$1,636 in reported general payments places this provider in the 70th percentile of 2,059 psychiatry providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Galantamine ErGalantamine Hbr | 111 | $10,401 |
| Memantine Hcl | 247 | $8,710 |
| Donepezil Hcl | 421 | $4,567 |
| RivastigmineRivastigmine Tartrate | 71 | $4,022 |
| Vilazodone Hcl | 16 | $3,167 |
| Rivastigmine | 19 | $2,903 |
| Memantine Hcl ErMemantine Hcl | 24 | $2,691 |
| Escitalopram Oxalate | 158 | $2,168 |
| Aripiprazole | 22 | $2,078 |
| Bupropion XlBupropion Hcl | 35 | $1,124 |
| Sertraline Hcl | 85 | $942 |
| Mirtazapine | 39 | $577 |
| Duloxetine Hcl | 25 | $565 |
| Quetiapine Fumarate | 36 | $415 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 27 | $372 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Tampa
- David SheehanTampa$631K
- Jamie FernandezTampa$418K
- Hardeep SinghTampa$374K
- Kenneth PagesTampa$274K
- Chetan GandhyTampa$94K
- Deborah Knudson GonzalezTampa$81K
- Andrew CutlerLakewood Ranch$5.7M
- Richard JacksonBoca Raton$3.6M
- Ilan MelnickCoral Gables$2.8M
- Todd BroderSt Augustine$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.